|
Array BioPharma: ARRY-502 Meets Primary And Secondary Endpoints In …
RTT News Array BioPharma Inc. (ARRY: Quote) announced positive results from a placebo-controlled, randomized, double-blind Phase 2 trial in mild to moderate persistent allergic asthma for ARRY-502, an oral CRTh2 antagonist. ARRY-502 achieved the primary … |
View full post on asthma – Google News